Saxenda (liraglutide 3.0 mg) carries a side-effect profile that extends well beyond the nausea and stomach upset most people expect during the first few weeks. While gastrointestinal symptoms remain the most common complaint, long-term use has been linked to gallbladder disease, pancreatic inflammation, possible psychiatric effects, bone and muscle loss, and nutritional shortfalls that develop gradually over months to years. The picture is complicated by the fact that some of these risks grow with duration of use, while others are highest early on and fade.
Gut Problems Are the Most Common and the Most Likely to Make You Quit
Nausea, vomiting, and diarrhea dominate the side-effect landscape for Saxenda. These gastrointestinal symptoms are not incidental; they stem from the same mechanism that makes the drug work. Liraglutide slows stomach emptying and reduces gut motility, which is a major part of how it creates a feeling of fullness and curbs appetite.1PubMed Central. Glucagon-like peptide-1 receptor agonists: Evolution, gastrointestinal adverse events, and future directions Most people notice these effects in the first few weeks as the dose is gradually increased, and for many the symptoms settle down. But a meaningful fraction of users never fully adjusts. In a real-world UK study of bariatric patients using Saxenda, about 15% discontinued specifically because of side effects.2British Journal of Diabetes. Liraglutide 3.0 (Saxenda) in bariatric patients: a retrospective real-world clinical evaluation of effectiveness In adolescents, the rate of gastrointestinal complaints was even higher, with roughly two-thirds of liraglutide-treated teens reporting gut-related events compared to about a third on placebo.3New England Journal of Medicine. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
In rare cases, the slowed stomach emptying goes beyond discomfort and tips into gastroparesis, where the stomach essentially stops moving food through efficiently. This has been documented even in younger patients, particularly at higher doses.4PubMed Central. Gastroparesis With the Initiation of Liraglutide: A Case Report If you develop persistent bloating, early fullness after just a few bites, or vomiting of food eaten hours earlier, those are signals to talk to your doctor rather than push through.
Gallbladder Disease and Pancreatitis
Gallstones and gallbladder inflammation are among the more serious concerns tied to prolonged Saxenda use. The risk appears to grow with higher doses and longer treatment duration.5PubMed Central. GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications Rapid weight loss itself raises gallstone risk regardless of how the weight comes off, but liraglutide may add to that baseline risk through effects on gallbladder motility and bile composition. A large multicentre cohort study found that liraglutide was associated with roughly a 40% higher risk of pancreatitis, cholangitis, or gallstones compared to non-users.6PubMed Central. GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study European pharmacovigilance data also found that liraglutide had a higher reporting frequency for gallbladder disorders than semaglutide.7PubMed. Real-world safety comparison of liraglutide and semaglutide in weight management: Insights from European pharmacovigilance data
Pancreatitis is the complication that tends to generate the most anxiety. Clinical trial data from the manufacturer found about 1.6 cases of acute pancreatitis per 1,000 patient-years of liraglutide exposure, compared to 0.7 per 1,000 patient-years for comparators.8PubMed Central. Liraglutide-Induced Pancreatitis: A Case Report and Literature Review That is roughly double the background rate, though still uncommon in absolute terms. Persistent, severe abdominal pain that radiates to the back and does not go away within a day warrants medical attention, particularly if you have a history of gallstones or heavy alcohol use.
The same multicentre cohort study found liraglutide was also associated with about a 46% higher risk of hepatic impairment.9PubMed Central. GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study Liver injury from Saxenda is not well characterized yet, but if you are on the drug long-term, periodic liver-function checks are reasonable, especially if you also take other medications that stress the liver.
The Thyroid Cancer Question
Saxenda’s prescribing label carries a boxed warning about thyroid C-cell tumors because liraglutide caused them in rodents. This has understandably alarmed many users, but the human evidence is substantially more reassuring. A comprehensive assessment pooling data from clinical trials covering over 100,000 participants found low absolute numbers of thyroid cancer events. The hazard ratio for all GLP-1 receptor agonists compared to placebo was 1.70, but the confidence interval just barely crossed statistical significance, and post-marketing surveillance data did not support an association between liraglutide use and thyroid cancer in adults.10PubMed Central. Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use When GLP-1 receptor agonist users were compared head-to-head with users of another diabetes drug class in a large US insurance database, there was no difference in thyroid cancer rates.
That said, the rodent finding was real, and the mechanism involves a receptor that human thyroid tissue does express, albeit to a much lesser degree than in rodent thyroid tissue. One study reviewing medical records of thyroid cancers in a liraglutide cohort found that most were papillary or a follicular variant of papillary, and microcarcinomas were more common in the liraglutide group (about two-thirds, versus 43% in comparators).11PubMed Central. Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population Whether this reflects more surveillance and incidental detection among liraglutide users or a genuine biological effect remains unclear. If you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, Saxenda is not appropriate for you. For everyone else, the current balance of evidence does not point to a meaningful thyroid cancer risk, but monitoring remains part of good clinical practice.
Mood, Anxiety, and Suicidal Thoughts
The psychiatric side of Saxenda’s safety profile has drawn increasing scrutiny. A pharmacovigilance analysis of reports submitted to the European drug safety database found that among psychiatric events linked to GLP-1 receptor agonists, depression was the most common, followed by anxiety and suicidal ideation. For liraglutide specifically, eight fatal outcomes were recorded in the database during the study period, mostly among men who completed suicide.12PubMed Central. Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database A separate analysis looking specifically at suicidal thoughts and self-injury found a disproportionality signal for liraglutide, with a reported odds ratio of 1.64.13PubMed. Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis
The multicentre cohort study mentioned earlier reinforced these signals, finding that liraglutide was associated with a 68% higher risk of anxiety disorder and a 51% higher risk of depressive disorder compared to non-users.14PubMed Central. GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study These are observational findings, which means they could be influenced by the fact that people seeking weight-loss treatment often have pre-existing mood vulnerabilities. Still, the consistency of the signal across different data sources makes it worth taking seriously. If you notice new or worsening depression, anxiety, or thoughts of self-harm while on Saxenda, do not dismiss them as unrelated to the medication.
Heart Rate Goes Up, but Cardiovascular Events Go Down
One side effect that surprises many users is an increase in resting heart rate. This has been documented repeatedly in clinical trials and is considered a genuine pharmacological effect of liraglutide. Despite this, the overall cardiovascular picture for liraglutide is favorable, at least in people with type 2 diabetes. The LEADER trial randomized over 9,300 patients with type 2 diabetes and high cardiovascular risk and found that liraglutide reduced the composite of major cardiovascular events, cardiovascular death, and all-cause mortality compared to placebo.15Cardiology Plus. Cardiovascular effects of anti-obesity medications: the perils and promise
The important caveat is that no trial has yet shown these cardiovascular benefits in people with obesity who do not also have diabetes. If you are using Saxenda purely for weight management, the heart-health upside demonstrated in LEADER may not apply to you. The elevated heart rate, on the other hand, likely does. For most people this increase is small and clinically insignificant, but if you already have a resting heart rate that concerns your doctor, or if you have a history of arrhythmia, the elevated rate is worth discussing.
Kidney Stress from Dehydration
Saxenda does not appear to damage the kidneys directly, but it can do so indirectly through the gastrointestinal symptoms it provokes. Severe or prolonged vomiting and diarrhea lead to dehydration, and dehydration can cause acute kidney injury. Case reports have documented this pathway, including one where a patient developed acute tubular necrosis requiring hemodialysis after weeks of worsening GI symptoms.16PubMed. Liraglutide-induced acute kidney injury In adolescents and patients with pre-existing kidney problems, the threshold for this kind of injury may be lower.17Pediatrics. Acute Kidney and Liver Injury Associated With Low-Dose Liraglutide in an Obese Adolescent Patient
The practical takeaway is straightforward: if you are experiencing persistent vomiting or diarrhea on Saxenda, aggressive fluid intake matters. If you cannot keep liquids down for more than a day, that is an urgent reason to seek medical attention rather than wait it out. People with chronic kidney disease should be particularly cautious during dose escalation, when GI symptoms tend to be most intense.
Muscle Loss, Bone Thinning, and Nutritional Gaps
Any treatment that causes significant weight loss will take some muscle along with the fat, and Saxenda is no exception. A review focused on older adults flagged this as a concern, noting that lean mass loss raises the specter of sarcopenia, the progressive loss of muscle strength and function that accelerates with aging.18PubMed Central. GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity A real-world study in South Korean patients found that fat loss was roughly three times larger than muscle loss in percentage terms, which is a better ratio than some other weight-loss methods, but muscle was still lost.19PubMed Central. Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia Resistance exercise during treatment is the most evidence-backed way to preserve muscle, and many obesity specialists now consider it a necessary companion to any GLP-1 receptor agonist prescription.
Bone health is another slow-burning concern. Preliminary findings suggest that GLP-1 receptor agonists cause modest reductions in bone mineral density and shift bone remodeling toward more breakdown than rebuilding, in a pattern that looks similar to what calorie restriction does on its own.20PubMed Central. Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity Whether this translates into more fractures over the long haul is simply not known yet. Most studies on GLP-1 receptor agonists and bone were done in people with diabetes, at lower doses, with short follow-up periods, and without bone outcomes as a primary endpoint.21PubMed. Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity The evidence is thin enough that no one can give a definitive answer, but if you are at elevated fracture risk already, bone density monitoring makes sense.
Nutritional deficiencies tie directly into both the muscle and bone concerns. A narrative review found that vitamin D deficiency was the most common nutritional shortfall in GLP-1 receptor agonist users, affecting about 7.5% at six months and rising to nearly 14% by one year. Iron stores dropped substantially, with ferritin levels 26 to 30% lower than in people taking a different class of diabetes drug. Over 60% of users consumed below estimated requirements for calcium and iron, and vitamin D intake averaged just 20% of recommendations. Protein intake was also frequently insufficient, contributing to lean mass loss.22PubMed. Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review Because Saxenda suppresses appetite so effectively, people tend to eat less of everything, including the nutrient-dense foods they need. Proactive supplementation and periodic blood work to check iron, vitamin D, and B12 levels can catch problems before they become symptomatic.
What Happens When You Stop
One of the less-discussed long-term consequences of Saxenda is what happens after you stop injecting. A systematic review and meta-analysis found that people with obesity who discontinued GLP-1 receptor agonists gained back an average of about 5.6 kg overall, with longer follow-up producing more regain: roughly 7.3 kg when tracked beyond 26 weeks, compared to about 2.5 kg in shorter windows. The weight rebound with liraglutide specifically was somewhat smaller than with semaglutide (about 4.3 kg versus 8.2 kg), but it was still substantial.23eClinicalMedicine. Metabolic and cardiovascular rebound following the discontinuation of GLP-1 receptor agonists: a systematic review and meta-analysis A narrative review of randomized studies confirmed that weight regain was rapid regardless of how long the treatment had lasted.24PubMed Central. Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies
The rebound is not just about the number on the scale. Blood sugar control, blood pressure, waist circumference, and other metabolic markers also deteriorated after stopping. Case reports illustrate how quickly this can happen: one patient regained more than her original starting weight within just three months of discontinuing Saxenda.25Journal of the ASEAN Federation of Endocrine Societies. Weight Rebound Post GLP-1 RA Cessation: The Importance of Gradual Tapering and Patient Education This does not mean Saxenda fails; it means the underlying biology driving obesity does not change while you are on the drug. Once the appetite-suppressing effect is removed, the old signals come roaring back. Some clinicians advocate gradual tapering rather than abrupt cessation, though rigorous evidence for that approach is still limited.
Skin Reactions and Immune Responses
Injection-site irritation is common enough to be expected, but skin effects can go beyond a red bump. A cross-sectional study of 254 people using GLP-1 receptor agonists found that about 40% reported at least one skin-related side effect. Dry skin was the most frequent complaint at about 21%, followed by itching and redness. Saxenda users had the highest rate of combined skin symptoms among the drugs studied.26Journal of Pakistan Association of Dermatologists. Skin manifestations associated with Glucagon-Like Peptide-1 (GLP-1) receptor agonist use for weight loss: A cross-sectional analysis Some of this is likely linked to the dehydration and nutritional changes that come with reduced food and fluid intake, rather than a direct drug effect on the skin.
True allergic reactions are less common but do occur. About 8.6% of patients in the large LEAD trials developed antibodies to liraglutide, though these antibodies were not associated with more adverse reactions, possibly because liraglutide shares roughly 97% of its structure with natural human GLP-1.27JCEM Case Reports. Delayed Type Hypersensitivity Reaction Induced By Liraglutide With Tolerance to Semaglutide Delayed-type hypersensitivity reactions have been reported, presenting as localized swelling, redness, and itching days after injection. In some of these cases, patients were able to switch to semaglutide without a recurrence, suggesting the reaction is specific to the liraglutide molecule rather than to the entire drug class.
Cancer Risk Beyond the Thyroid
The long-term relationship between GLP-1 receptor agonists and cancer overall is an area where the evidence is still developing and where findings are somewhat mixed depending on time horizon. A nationwide emulated trial from Denmark compared long-term GLP-1 receptor agonist users with users of another drug class and found that overall cancer risk was similar for the first six years. Beyond six years, however, the hazard ratio rose to 1.35, with the absolute risk difference reaching about 4 additional cancer cases per 100 users over a 10-year period.28The Lancet Regional Health – Europe. Long-term glucagon-like peptide-1 receptor agonist use and overall cancer risk: a nationwide emulated trial This is a single observational study, and the authors were careful to note the limitations of their design. It is too early to say whether this reflects a genuine long-term cancer signal or confounding factors that accumulate over a decade of follow-up. But it is the kind of finding that ensures researchers will keep watching closely.
Meanwhile, a real-world UK study found no new safety concerns with Saxenda and Victoza use.29PubMed Central. Real-world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases European pharmacovigilance data found no significant difference between liraglutide and semaglutide for pancreatic tumor reports.30PubMed. Real-world safety comparison of liraglutide and semaglutide in weight management: Insights from European pharmacovigilance data For now, the cancer picture is watchful rather than alarming, but anyone on Saxenda for multiple years should keep up with routine cancer screening.
Pregnancy and Fertility Considerations
Saxenda is not approved for use during pregnancy, and the manufacturer recommends stopping it at least two months before attempting to conceive. In animal studies, exposure to GLP-1 receptor agonists during pregnancy caused decreased fetal growth, skeletal and visceral abnormalities, and embryonic death.31PubMed. Glucagon-like peptide-1 receptor agonist use in pregnancy: a review The human data, which comes entirely from pregnancies that happened accidentally during clinical trials rather than planned use, is more reassuring. A review of regulatory trial data found that the rate of congenital abnormalities appeared relatively low following inadvertent exposure.32PubMed Central. Glucagon-like peptide 1 (GLP-1) receptor agonists’ use during pregnancy: Safety data from regulatory clinical trials A large population-based study comparing GLP-1 receptor agonist exposure around conception with insulin exposure in pregnancies complicated by type 2 diabetes did not find a significantly increased risk of major congenital malformations.
One case report documented a woman who took the full 3 mg daily dose of Saxenda through seven weeks of pregnancy. Her child’s neurodevelopmental assessment at 14 months was normal.33PubMed Central. Exposure to High-Dose Liraglutide in a Pregnant Woman With Obesity That is just one case and cannot be generalized, but it adds to a small body of data suggesting that early inadvertent exposure does not inevitably cause harm. The practical reality is that Saxenda can improve fertility indirectly by inducing weight loss, which means pregnancies sometimes happen when people are not expecting them. If you are of reproductive age and on Saxenda, reliable contraception is important, and stopping the drug promptly if pregnancy is confirmed remains the standard recommendation.
Vision Changes
An underappreciated finding from the multicentre cohort data is a link between liraglutide and vision impairment, with a roughly 34% higher risk compared to non-users.34PubMed Central. GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study In the context of diabetes treatment, rapid improvements in blood sugar control have long been known to temporarily worsen diabetic retinopathy, and a similar mechanism could be at play here. For people without diabetes, the visual effects are less well understood. If you notice blurred vision, floaters, or other changes that develop after starting Saxenda, mention it to your prescriber. It may not be the first thing either of you associates with a weight-loss injection, but the data suggest the connection is real enough to take seriously.